131276A Novel agent for the treatment of CDifficile infectionClosedFeasibility StudiesInnovate UKClostridium difficile (C.Diff) Associated Diarrhoea (CDAD) is a severe form of diarrhoea which can prove fatal. Prevalence has been increasing since the late 1990s, and it is increasingly occurring outside of hospital and in previously low-risk groups. Valevia is developing a drug which has demonstrated efficacy against hyper-virulent strains of C.Diff and strains with reduced susceptibility to current therapies, is rapidly bactericidal and shows no cross resistance to currently used antibiotic classes. This project will further characterise its pharmacological profile, validate its potential to address currently unmet medical needs in CDAD and design a clinical development plan enabling the earliest possible Registration.